Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PARP”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT06334809
What this trial is testing

INSIDE: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations

Who this might be right for
Prostate Cancer
Fondazione del Piemonte per l'Oncologia 400
Not applicableUnknownNCT04752865
What this trial is testing

Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer

Who this might be right for
Ovarian Cancer
Hellenic Cooperative Oncology Group 50
Not applicableNot Yet RecruitingNCT07757711
What this trial is testing

Implementation of New Models of Ovarian Carcinoma Resistant to Therapy

Who this might be right for
Ovarian Cancer
Mario Negri Institute for Pharmacological Research 50
Not applicableStudy completedNCT04774406
What this trial is testing

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

Who this might be right for
Cancer
University Hospital, Caen 2,336
Early research (Phase 1)Study completedNCT01390571
What this trial is testing

Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma

Who this might be right for
Brain and Central Nervous System Tumors
Cancer Research UK 34
Testing effectiveness (Phase 2)Study completedNCT03562832
What this trial is testing

Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP

Who this might be right for
Metastatic Breast Cancer
Allarity Therapeutics 20
Early research (Phase 1)Looking for participantsNCT05053854
What this trial is testing

PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours

Who this might be right for
Neuroendocrine Tumors
Peter MacCallum Cancer Centre, Australia 24
Testing effectiveness (Phase 2)Looking for participantsNCT07359066
What this trial is testing

An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsPARP Inhibitor
Shanghai SciBrunch Therapeutics Co., Ltd. 210
Testing effectiveness (Phase 2)WithdrawnNCT02127151
What this trial is testing

A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer

Who this might be right for
Endometrial Cancer
University College, London
Early research (Phase 1)Study completedNCT02575651
What this trial is testing

A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies

Who this might be right for
Advanced Solid Malignancies
Jiangsu HengRui Medicine Co., Ltd. 79
Testing effectiveness (Phase 2)Ended earlyNCT03875313
What this trial is testing

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Who this might be right for
Solid TumorClear Cell Renal Cell CarcinomaTNBC - Triple-Negative Breast Cancer+4 more
Calithera Biosciences, Inc 33
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06063070
What this trial is testing

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Who this might be right for
Ovarian CancerHigh Grade Serous Adenocarcinoma of OvaryHigh Grade Endometrioid Ovarian Cancer+2 more
Sun Yat-sen University 44
Testing effectiveness (Phase 2)UnknownNCT05065021
What this trial is testing

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer+2 more
University Health Network, Toronto 40
Not applicableUnknownNCT04790955
What this trial is testing

Effect of Combination Therapy on SCLC After Initial Treatment Failure

Who this might be right for
Small-cell Lung Cancer
First Affiliated Hospital of Harbin Medical University 48
Post-approval studies (Phase 4)Study completedNCT03752216
What this trial is testing

NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.

Who this might be right for
Ovarian Cancer
ARCAGY/ GINECO GROUP 141
Testing effectiveness (Phase 2)Active Not RecruitingNCT05498272
What this trial is testing

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

Who this might be right for
Prostate CancerBRCA1 MutationBRCA2 Mutation+2 more
Rana McKay, MD 32
Early research (Phase 1)Study completedNCT01145430
What this trial is testing

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeMale Breast Carcinoma+7 more
National Cancer Institute (NCI) 45
Early research (Phase 1)Study completedNCT02986100
What this trial is testing

Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib

Who this might be right for
Solid Tumor
pharmaand GmbH 6
Early research (Phase 1)Study completedNCT02723864
What this trial is testing

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

Who this might be right for
Neoplasms
National Cancer Institute (NCI) 53
Early research (Phase 1)Study completedNCT01664000
What this trial is testing

A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumors
Cellceutix Corporation 48
Next Page